Ben Mullish
@bhmullish.bsky.social
MRC Clinician Scientist Fellow and Honorary Consultant in Hepatology and Gastroenterology, based at Imperial College London. All comments in a personal capacity.
Reposted by Ben Mullish
We’ve also written a Behind the Paper blog post to accompany our article, which you can find here: go.nature.com/401ctsa
Antibiotics fuel the rise of vancomycin-resistant enterococci intestinal colonisation by remodelling the metabolic landscape of the gut microbiome
Antibiotics save lives- but also reshape the gut microbiome, unintentionally promoting VRE colonisation. This study reveals how antibiotic-driven metabolic shifts promote VRE expansion and highlights ...
go.nature.com
July 22, 2025 at 9:12 AM
We’ve also written a Behind the Paper blog post to accompany our article, which you can find here: go.nature.com/401ctsa
And keeping an open mind about other therapeutic strategies, including vancomycin - read more about work by @nabilquraishi.bsky.social and colleagues on this here: bsky.app/profile/bhmu...
Great work by Nabil Quraishi, Palak Trivedi and many others - unravelling the positive impact of #vancomycin in #PSC #IBD by altering interactions between the host, #microbiome, and #metabolome. Now in #JCC: academic.oup.com/ecco-jcc/adv... #GastroSky
Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures
AbstractBackground. We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV
academic.oup.com
May 10, 2025 at 6:33 AM
And keeping an open mind about other therapeutic strategies, including vancomycin - read more about work by @nabilquraishi.bsky.social and colleagues on this here: bsky.app/profile/bhmu...
Well - for one - looking forward to the results of the FARGO trial @cholestasisdoc.bsky.social @pscsupport.bsky.social: bsky.app/profile/bhmu...
Pleased that #FARGO - a randomised, multicentre, placebo-controlled phase IIa trial of #FMT to treat #PSC - is running and recruiting. Have a look at the protocol paper out now in #BMJOpen: doi.org/10.1136/bmjo... @pscsupport.bsky.social @cholestasisdoc.bsky.social
FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial
Introduction Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD). The strong association between gut and liver inflammation has driven...
doi.org
May 10, 2025 at 6:33 AM
Well - for one - looking forward to the results of the FARGO trial @cholestasisdoc.bsky.social @pscsupport.bsky.social: bsky.app/profile/bhmu...
Reposted by Ben Mullish
Want to know more about why we are looking at the #GutMicrobiome #IMT #HCT as therapy? Find out even more here: youtu.be/zDd1qdVCa6A?...
youtu.be
March 19, 2025 at 5:38 PM
Want to know more about why we are looking at the #GutMicrobiome #IMT #HCT as therapy? Find out even more here: youtu.be/zDd1qdVCa6A?...